Leaving the study early · female and male 55‐59 year old (mean) patients with various psychiatric conditions and antipsychotic‐induced tardive dyskinesia
It is very uncertain whether POLYPEPTIDE ‐ CERULETIDE changes acceptability of treatment (measured by participants leaving the… compared with PLACEBO (very low certainty).
1 finding from 1 review
Leaving the study early · female and male 59‐80 (mean) years old patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether ALKALOID ‐ DIHYDROGENATED ERGOT ALKALOIDS changes acceptability of treatment (measured by participants leaving the… compared with PLACEBO (very low certainty).
1 finding from 1 review
Leaving the study early · female and male 35 (mean) years old patients with schizophrenia and tardive dyskinesia, acute extrapyramidal symptoms, and/or…
1 finding from 1 review
Leaving the study early · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether ANTIEPILEPTIC ‐ LEVETIRACETAM changes acceptability of treatment (measured by participants leaving the… compared with PLACEBO (very low certainty).
1 finding from 1 review
Leaving the study early · psychiatric patients (schizophrenia) with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether switch to another antipsychotic changes acceptability of the treatment: leaving the study early compared with antipsychotic cessation (very low certainty).
1 finding from 1 review
Leaving the study early · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Leaving the study early · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether specific antipsychotic changes acceptability of the treatment: leaving the study early compared with other drugs (very low certainty).
1 finding from 1 review
Leaving the study early · female and male 42 (mean) years old patients with schizophrenia or schizoaffective disorder and antipsychotic‐induced tardive dyskinesia
It is very uncertain whether reduced dose of antipsychotics changes acceptability of the treatment: leaving the study early compared with antipsychotic maintenance (very low certainty).
1 finding from 1 review
RR 0.33 [0.06, 1.99]
1 study · 8 participants
Very low
Satisfaction with treatment: leaving the study early Endpoint data (events) · patients with schizophrenia
CBT may leads to lower satisfaction with treatment ‐ leaving the study early for any reason compared with ALL OTHER PSYCHOLOGICAL THERAPIES (low certainty).
1 finding from 1 review
Leaving the study early ‐ short term ‐ due to lack of efficacy · patients with schizophrenia
It is very uncertain whether haloperidol changes leaving the study early due to inefficacy of treatment as a measure… compared with first‐generation antipsychotics (very low certainty).
1 finding from 1 review
Leaving the study early ‐ medium term ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Behaviour: Leaving the study early (short‐term) · patients with depression
Music therapy plus treatment as usual (TAU) showed no clear difference in leaving the study early Up to 3 months compared with TAU (moderate certainty).
1 finding from 1 review
Breathlessness ‐ early effect VAS 0‐10. Scale from: 0 to 10. · exacerbations of COPD
1 finding from 1 review
Leaving the study early · patients with sexual dysfunction due to antipsychotic drug therapy
It is very uncertain whether ADJUNCTIVE TREATMENT ‐ SPECIFIC: SILDENAFIL changes leaving the study early compared with PLACEBO (very low certainty).
1 finding from 1 review
Leaving the study early · patients with sexual dysfunction due to antipsychotic drug therapy
1 finding from 1 review
Leaving the study early · Adolescents with psychosis
PSYCHOEDUCATIONAL (PE) + MULTIFAMILY TREATMENT (MFT) showed no clear difference in leaving the study early: For any reason compared with NONSTRUCTURED GROUP THERAPY (NSGT, all long‐term) (low certainty).
1 finding from 1 review
Leaving the study early · Adolescents with psychosis
It is very uncertain whether COGNITIVE REMEDIATION THERAPY (CRG) + TREATMENT‐AS‐USUAL (TAU) changes leaving the study early: For any reason compared with TAU (all short‐term) (very low certainty).
1 finding from 1 review
Blood loss: post‐treatment haematocrit (%) · early fetal death (less than 24 weeks)
1 finding from 1 review
Leaving the study early · Adolescents with psychosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Sepsis · preterm infants with or at risk of respiratory distress syndrome
Inositol supplementation to preterm infants (repeat doses in any… showed no clear difference in sepsis (early or late onset) compared with control (moderate certainty).
1 finding from 1 review